<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418195</url>
  </required_header>
  <id_info>
    <org_study_id>F141029007</org_study_id>
    <secondary_id>1R01MH107183-01</secondary_id>
    <nct_id>NCT02418195</nct_id>
  </id_info>
  <brief_title>miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome</brief_title>
  <official_title>Plasma Exosomal MicroRNAs as Promising Novel Biomarkers for Suicidality and Treatment Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether neural-derived exosomal miRNAs are&#xD;
      differentially expressed that are specific to suicidal ideation or behavior, and which by&#xD;
      affecting specific miRNA targets and pathways, are associated with suicidal behavior and&#xD;
      response to ketamine. The following groups of subjects will be examined: 1) major depressive&#xD;
      disorder (MDD) with a recent suicide attempt (in past 2 weeks), 2) MDD with serious ideation&#xD;
      (in the past 7 days) without recent suicide attempt (in the past 6 months), 3) MDD without&#xD;
      clinically significant suicidal ideation (in the past 7 days) or recent suicide attempt (in&#xD;
      the past 6 months), and 4) healthy controls. Both suicidal and non-suicidal MDD will be given&#xD;
      ketamine (0.5 mg/kg, IV) and blood will be drawn at predose, 30 min, 180 min, 24 hours, and&#xD;
      14 days post-infusion to measure changes in miRNAs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neural miRNAs are responsive to environmental, synaptic, and pathological changes and can be&#xD;
      actively secreted by cells such as exosomes from brain into blood. These exosomes bear&#xD;
      cell-type specific surface markers. Using a neural specific surface marker, the investigators&#xD;
      successfully isolated neural-derived exosomes and found that these exosomes are enriched with&#xD;
      miRNAs/mRNAs that are expressed in brain. Using this novel approach the investigators aim to&#xD;
      examine whether neural derived exosomal miRNAs are differentially expressed that are specific&#xD;
      to suicidal ideation or behavior, and which by affecting specific mRNA targets and pathways,&#xD;
      are associated with suicidal behavior and response to ketamine.&#xD;
&#xD;
      The following groups of subjects will be examined: 1) major depressive disorder (MDD) with a&#xD;
      recent suicide attempt (in past 2 weeks), 2) MDD with serious ideation (in the past 7 days)&#xD;
      without recent suicide attempt (in the past 6 months), 3) MDD without clinically significant&#xD;
      suicidal ideation (in the past 7 days) or suicide attempt in the past 6 months, and 4)&#xD;
      healthy controls. Both suicidal and non-suicidal MDD will be given ketamine (0.5 mg/kg, IV)&#xD;
      and blood will be drawn at pre-infusion, 30 minutes and 180 minutes post-infusion to measure&#xD;
      changes in miRNAs. Healthy controls will have a one-time blood draw. The investigators also&#xD;
      propose a parallel human postmortem brain study to examine whether changes in miRNAs in&#xD;
      suicidality correspond to miRNA changes in brain by comparing dlPFC and hippocampus from MDD&#xD;
      suicide, MDD non-suicide, and control subjects.&#xD;
&#xD;
      With this the investigators attempt to discover 1) whether suicidal ideation or behavior is&#xD;
      associated with differences in the expression of specific miRNAs, 2) whether&#xD;
      anti-suicidal/antidepressant effects of ketamine is associated with miRNAs changes, and 3)&#xD;
      whether miRNA/mRNA-regulatory pathways contribute to suicide pathogenesis and treatment&#xD;
      response. Our study will provide a novel avenue for the development of miRNAs as ''molecular&#xD;
      tool'' to identify suicidality and treatment response and in generating target based&#xD;
      therapies to treat this devastating disorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 20, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beck Scale for Suicide Ideation (BSS)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory (BAI)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Hopelessness Scale (BHS)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-item Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician-Administered Dissociative States Scale (CADSS)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systematic Assessment for Treatment Emergent Events (SAFTEE)</measure>
    <time_frame>180 minutes post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>MDD with recent Suicide Attempt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects with Major Depressive Disorder with a recent Suicide Attempt (in the past 2 weeks) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD with Suicidal Ideation no attempt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects with Major Depressive Disorder with recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD without Suicidal Ideation no attempt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects with Major Depressive Disorder without recent Suicidal Ideation (in the past 7 days) without a recent Suicide Attempt (in the past 6 months) will receive a one-time IV infusion of ketamine at a dose of 0.5mg/kg at a rate of 40mL over 40 minutes. Blood will be drawn at pre-dose, 30 minutes post dose, 180 minutes post dose, 24 hours post dose, and 14 days post dose to measure changes in miRNAs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy Control subjects without a psychiatric diagnosis will have a one-time blood draw to examine miRNAs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine</intervention_name>
    <description>IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes</description>
    <arm_group_label>MDD with Suicidal Ideation no attempt</arm_group_label>
    <arm_group_label>MDD with recent Suicide Attempt</arm_group_label>
    <arm_group_label>MDD without Suicidal Ideation no attempt</arm_group_label>
    <other_name>ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65&#xD;
&#xD;
          2. Physically healthy and capable of undergoing ketamine infusion&#xD;
&#xD;
          3. Willing and able to provide informed consent&#xD;
&#xD;
          4. Diagnosis of MDE as determined by the MINI (MDD participants)&#xD;
&#xD;
          5. HAM-D 21 score ≥ 16 (MDD participants)&#xD;
&#xD;
          6. Suicide attempt occurred within past 2 weeks (MDD Participants with Suicide Attempt)&#xD;
&#xD;
          7. For the time frame of the past 7 days, C-SSRS score ≥ 3 (MDD Participants without&#xD;
             Suicide Attempt, with Suicidal Ideation)&#xD;
&#xD;
          8. For the time frame of the past 7 days, C-SSRS score &lt; 3 (MDD Participants without&#xD;
             Suicide Attempt, without SUicidal Ideation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. Post-partum state (being within 2 months of delivery or miscarriage)&#xD;
&#xD;
          3. Homicide risk as determined by clinical interview&#xD;
&#xD;
          4. A lifetime history of psychotic disorder&#xD;
&#xD;
          5. Any history of dissociation or dissociative disorder&#xD;
&#xD;
          6. Bipolar disorder&#xD;
&#xD;
          7. Pervasive developmental disorder&#xD;
&#xD;
          8. Cognitive disorder&#xD;
&#xD;
          9. Cluster A personality disorder&#xD;
&#xD;
         10. Anorexia nervosa&#xD;
&#xD;
         11. Treatment with one of the following medications, known to affect the glutamate-NMDA&#xD;
             receptor system (specifically: lamotrigine, acamprosate, memantine, riluzole, or&#xD;
             lithium)&#xD;
&#xD;
         12. Alcohol or drug dependence (except nicotine and caffeine) within the last month or the&#xD;
             use of any hallucinogen (except cannabis), including phencyclidine in the last month&#xD;
&#xD;
         13. Any known hypersensitivity or serious adverse effect associated with ketamine&#xD;
             treatment&#xD;
&#xD;
         14. Any clinically-significant medication condition or therapy that would preclude&#xD;
             treatment with ketamine, to include: Recent myocardial infarction&#xD;
&#xD;
         15. Unstable angina&#xD;
&#xD;
         16. Active neoplasm in the past 6 months&#xD;
&#xD;
         17. Immunosuppressive or corticosteroid therapy within the last month, with the following&#xD;
             exceptions: any inhaled, intranasal, topical or vaginal corticosteroids are allowed.&#xD;
&#xD;
         18. Chemotherapy&#xD;
&#xD;
         19. Head injury of loss of consciousness in the past 6 months&#xD;
&#xD;
         20. If the subject reports any of the following disorders:&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Lupus erythematosus&#xD;
&#xD;
               -  Autoimmune hepatitis&#xD;
&#xD;
               -  Autoimmune peripheral neuropathy&#xD;
&#xD;
               -  Autoimmune pancreatitis&#xD;
&#xD;
               -  Behcet's disease&#xD;
&#xD;
               -  Chrohn's disease&#xD;
&#xD;
               -  Autoimmune glomerulonephritis&#xD;
&#xD;
               -  Grave's disease&#xD;
&#xD;
               -  Guillain-Barre syndrome (if active)&#xD;
&#xD;
               -  Hashimoto's thyroiditis&#xD;
&#xD;
               -  Autoimmune polymyositis or polymyalgia (fibromyalgia is OK)&#xD;
&#xD;
               -  Myasthenia gravis&#xD;
&#xD;
               -  Narcolepsy&#xD;
&#xD;
               -  Polyarteritis nodosa&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Sjogren's syndrome&#xD;
&#xD;
               -  Transverse myelitis&#xD;
&#xD;
               -  Wegener's granulomatosis&#xD;
&#xD;
               -  HIstory of seizures (only childhood febrile seizures allowed)&#xD;
&#xD;
               -  (HIV and Hepatitis are OK if stable)&#xD;
&#xD;
         21. Systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt;90 at screening&#xD;
&#xD;
         22. A QTc &gt; 480 msec as determined by an ECG&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yogesh Dwivedi, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard C Shelton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Yogesh Dwivedi, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Ketamine</keyword>
  <keyword>Suicide Attempt</keyword>
  <keyword>Suicidal Ideation</keyword>
  <keyword>Suicidality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

